Journal: Materials today. Bio

Article Title: Precise delivery of doxorubicin and imiquimod through pH-responsive tumor microenvironment-active targeting micelles for chemo- and immunotherapy.

doi: 10.1016/j.mtbio.2022.100482

Figure Lengend Snippet: Fig. 10. Immunostaining of tumor tissues in tumor-bearing mice after treatments. (A) Immunohistochemistry images of tumor sections stained with CD3, CD8, and TNF-α antibodies. The scale bar is 100 μm. (B) Immunofluorescence images of tumor tissues after treatments for 12 days. The scale bar is 50 μm. Blue fluorescence represents the cell nucleus stained with DAPI. Green fluorescence represents the iNOS stained with the iNOS antibody conjugated with FITC.

Article Snippet: After 30 min, the tissue slice was stained with diluted iNOS antibody (Miltenyi Biotec, catalog: 130-116-357) at 4 C overnight.

Techniques: Immunostaining, Immunohistochemistry, Staining

Journal: Pharmaceuticals

Article Title: Anti-Inflammatory and Antioxidant Effects of Topical Formulations Containing Plant Extracts, Methylsulfonylmethane, and Peptiskin® in In Vitro Models of Arthritis

doi: 10.3390/ph18091270

Figure Lengend Snippet: Figure 8. Protective effect of AS632 against TNF-α/IL-1β-induced inflammatory responses in C28/I2 chondrocytes. C28/I2 chondrocytes were pre-treated with empty liposomes (ELs), AS632, or AS633 at a concentration of 1 µL/mL or 1 µM dexamethasone as a positive control for 2 h, followed by stimulation with 1 ng/mL IL-1β and 10 ng/mL TNF-α. (A) After 6 h of treatment, total RNA was extracted, and the mRNA expression levels of IL-6, TNF-α, and IL-1β were analyzed by real-time qPCR. (B) After 24 h of treatment, cells were lysed, and protein levels of MMP-3, MMP-13, and iNOS were analyzed by Western blotting. * p < 0.05; ** p < 0.01 compared to the cytokine-treated control group.

Article Snippet: Antibodies against iNOS (Cat. No. sc-7271) and MMP-9 (Cat. No. sc-13520) were acquired from Santa Cruz Biotechnology (Dallas, TX, USA), while the MMP-3 antibody (Cat. No. LS-C27030-200) was obtained from LS Bio (Seattle, WA, USA).

Techniques: Liposomes, Concentration Assay, Positive Control, Expressing, Western Blot, Control

Journal: Journal of Tissue Engineering

Article Title: Formation of neutrophil extracellular traps in the early stages exacerbate the healing process by regulating macrophage polarization in Achilles tendon-bone injury

doi: 10.1177/20417314251348038

Figure Lengend Snippet: PAD4 inhibition reduces M1 macrophage polarization after tendon-bone injury. (a) Immunohistochemistry (IHC) analysis of CD68 in tendon-bone section from control, TI, and TI + PAD4 inhibitor groups. (b) Quantification of CD11c positive cells. n = 6 mice/group. (c) IHC analysis of CD11c in tendon section from control, TI, and TI + PAD4 inhibitor groups. (d) Quantitative analysis of CD11c positive cells in c. n = 6 mice/group. (e) Western blot of iNOS, TLR4 and IL-1β in tendon tissue from control, TI, and TI + PAD4 inhibitor groups. (f) Quantification of relative gray intensity/GAPDH in c. n = 3 mice/group. Data are presented as the mean ± SEM. Scale bar = 1 mm. Significance was examined by one-way ANOVA (b, d, and f). ** P < 0.01, **** p < 0.0001.

Article Snippet: For M1 macrophages detection, sections were incubated with CD68 (14-0681-82; Invitrogen), CD11c (14-0114-82, Invitrogen), and iNOS (MAB9502; R&D systems) antibodies.

Techniques: Inhibition, Immunohistochemistry, Control, Western Blot

Journal: Italian Journal of Animal Science

Article Title: Protective effect of chitosan oligosaccharide against oxidative damage of peripheral blood mononuclear cells in dairy cows induced by diethylenetriamine/nitric oxide via NF-κB signalling pathway

doi: 10.1080/1828051x.2020.1772131

Figure Lengend Snippet: Figure 2. Effects of chitosan oligosaccharideon on the phosphorylation level of NF-kB pathway, the protein expression level of nitric oxide synthase (iNOS) and interleukin-1b (IL-1b). Expressions of IL-1b(A); phosphorylated IjB kinase b (P-IKKb) (B); phosphorylated inhibitor of nuclear factor kappa-Ba (P-IjBa) (C); phosphorylated nuclear factor kappa-Bp65(P-NF-jBp65) (D); iNOS (E), protein levels were detected by western blotting and normalised to beta-actin (b-Actin) levels. CTR¼ control treatment, without chitosan oligosacchar- ides addition; COS40, COS80, COS160, and COS320¼ treated with 40, 80, 160, and 320lg/mL chitosan oligosaccharides respectively.

Article Snippet: The membranes were incubated in the following primary antibodies: primary polyclonal rabbit anti-iNOS antibody (NBP1-97471, Novus Biological, USA), rabbit anti-IL-1b (Cell Signalling Technology, Boston, MA), anti-IKKb, monoclonal rat anti-IjBa, monoclonal rabbit anti-NF-jBp65 antibody(NF-jB pathway Sampler Kit 9963,CST, MA), anti-phospho-IKKb, anti-phospho-IjBa, and anti-phospho-NF-jBp65 (NF-jB pathway Sampler Kit 9963, CST, MA).

Techniques: Phospho-proteomics, Expressing, Western Blot, Control

Journal: Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society

Article Title: Efficacy of wearable vibration dressings on full-thickness wound healing in a hyperglycemic rat model.

doi: 10.1111/wrr.13129

Figure Lengend Snippet: FIGURE 6 Improvement in inflammation using the wearable vibration dressing. (A) Representative immunofluorescence images of CD68+/ iNOS+ macrophages (merged red and green), CD163+ macrophages (green), and DAPI (blue) nuclear staining in the control and vibration groups. White arrowheads indicated CD68+/iNOS+ macrophages. Scale bar = 100 μm. (B) Quantitative analysis of CD68+/iNOS+ and CD163+

Article Snippet: See the T erm s and C onditions (https://onlinelibrary.w iley.com /term s-and-conditions) on W iley O nline L ibrary for rules of use; O A articles are governed by the applicable C reative C om m ons L icense reagents used in the study are as follows: (1) primary antibodies: CD31/PECAM-1 antibody (rabbit-polyclonal, NB1002284), CD68/ SR-D1 antibody (ED1) (mouse-monoclonal, NB600-985-0.025), and iNOS antibody (rabbit-polyclonal, NBP300-605) from Novus Biologicals (Centennial, CO), CD163 (EPR19518) (rabbit-monoclonal, ab182422, Abcam, Cambridge, UK); (2) secondary antibodies: Alexa Fluor® 488 fluorescent antibody (donkey, anti-rabbit IgG, code: 11-545-152) and Alexa Fluor® 594 fluorescent antibody (donkey, anti-mouse IgG, code: 15-585-151) from Jackson ImmunoResearch (West Grove, PA).

Techniques: Immunofluorescence, Staining, Control